Stem cell therapy targets brain metastatic melanomas
May 31, 2023 -- Twin stem cells acting in unison may activate the immune system to suppress metastatic melanoma tumor growth in the brain, according to Department of Defense-funded research, published Wednesday in Science Translational Medicine. The procedure prolonged survival in preclinical trials on mice, indicating that locally delivered immunotherapies may be beneficial in brain metastases treatment. Read More
FDA approves first topical gene therapy for treatment of wounds in patients with dystrophic epidermolysis bullosa
May 19, 2023 -- The U.S. Food and Drug Administration (FDA) said on Friday it has approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients six months of age and older with dystrophic epidermolysis bullosa (DEB) and with mutations in the collagen type VII alpha 1 chain (COL7A1) gene. Read More
Revvity, AstraZeneca ink license agreement for next-gen base editing tech
May 19, 2023 -- Revvity this week announced a nonexclusive license agreement with AstraZeneca for the technology underlying a next-generation modular gene editing platform. Read More
Researchers map RNA to inform selection of stem cells for therapeutic applications
May 12, 2023 -- Creating maps of the RNA inside cells could improve cell therapies by enabling the isolation of subsets of cells with similar characteristics, according to a study published Friday in Cell Reports Methods. Read More
Getting to know the Association of Biomolecular Resource Facilities (ABRF)
May 4, 2023 -- The Association of Biomolecular Resource Facilities (ABRF) will hold its Annual Meeting May 7 to May 10 in Boston. ABRF is a membership organization that brings together Core facilities across the U.S. and supports more than 2,400 members at over 400 institutions including organizations in government, academia, research, industry, and commercial settings. Over 50% of its members define their area of professional responsibility as either genomics or core administration. Read More
Bio-Techne fiscal Q3 sales rise 1% on strength in cell therapy, prostate test products
May 3, 2023 -- Bio-Techne on Wednesday reported fiscal third-quarter sales of $294.1 million, up 1% compared to $290.4 million in the prior-year quarter and short of analysts’ average estimate of $296.7 million. Read More
Dual CRISPR gene-editing therapy eliminates HIV infections in mice
May 2, 2023 -- Combining a dual CRISPR gene-editing therapy with antiretroviral drugs can eliminate HIV infections in mice, according to a study published in the Proceedings of the National Academy of Sciences. Read More
Viral peptides improve CRISPR-Cas gene editing to expand cell therapy applications
May 1, 2023 -- Scientists have used viral peptides to get CRISPR-Cas gene editing molecules into cells more efficiently and with minimal toxicity, suggesting the method can improve the production of cell and gene therapies. Read More
Researchers modify lentivirus to enable targeted delivery of muscle disease gene therapy
April 28, 2023 -- Researchers have created a lentiviral gene therapy vector capable of targeting muscle cells to treat the rare disease Duchenne muscular dystrophy (DMD) in mice. Read More
Reanalysis of old data reveals overlooked liver gene therapy vector with better properties
April 26, 2023 -- Rational design and directed evolution have created an adeno-associated virus (AAV) capsid that is better at targeting the liver, setting the stage for its use as a gene therapy vector. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter